Biocon retains economic interest in global commercialization of Hulio in-licensed by Mylan
Biocon is retaining economic interest in global commercialization of Hulio, (biosimilar Adalimumab) in-licensed by Mylan. Following the successful approval and European launch of Hulio, (biosimilar Adalimumab) in-licensed by the company’s partner Mylan from Fujifilm Kyowa Kirin Biologics, the commercialization rights have been extended from Europe to Global Markets. Biocon, under the terms of its global … Read more